Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10273-10279

  Cutrone, Rochelle ^a   Lednicky, John ^a   Dunn, Glynis ^c   Rizzo, Paola ^b   Bocchetta, Maurizio ^a   Chumakov, Konstantin ^d   Minor, Philip ^c   Carbone, Michele ^a,e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG SYNTHESIS; LABORATORY TEST; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIMIAN VIRUS; SIMIAN VIRUS 40; VIRUS INACTIVATION; WORLD HEALTH ORGANIZATION;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DNA, VIRAL; DRUG CONTAMINATION; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTIONS; SIMIAN VIRUS 40; TRANSFECTION; TUMOR VIRUS INFECTIONS;

EID: 28544444596     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2028     Document Type: Article

References (38)

1. Gazdar A, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat Rev Cancer 2002;2:957-64.
2. Carbone M, Rizzo P, Pass HI. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 1997;15:1877-88.
3. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973;1:115-8.
4. Boockchin D, Scumacher J. The virus and the vaccine. New York: St. Martin Press; 2004. ISBN 0-31-227872-1.
5. Chumakov MP, Dzagurov SG, Lashkevich VA, et al. Methods and results of production of live poliomyelitis vaccine which does not contain the traces of vacuolizing virus SV40 [in Russian]. Vopr Virusol 1963;4:445-9.
6. Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene 2002;21:1141-9.
7. Wong M, Pagano JS, Schiller JT, Tevethia SS, Raab-Traub N, Gruber J. New associations of human papillomavirus, simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst 2002;94:1832-6.
8. Institute of Medicine, Immunization Safety Review Committee. Washington (DC): National Academy Press; 2003. Available from: http://www.nap.edu.
9. Rizzo P, Di Resta I, Powers A, Ratner H, Carbone M. Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current testing for SV40 infection. Cancer Res 1999;59:6103-8.
10. Sangar D, Pipkin PA, Wood DJ, Minor PD. Examination of poliovirus vaccine preparations for SV40 sequences. Biologicals 1999;27:1-10.
11. Sierra-Honigmann A, Krause P. Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA. Biologicals 2000;28:1-4.
12. Grachev VP, Karganova GG, Rumyantsev AA, Ivanova OE, Eremeeva TP, Drozdov SG. Evaluation of the new control methods for oral poliomyelitis vaccine. Dev Biol Stand 2001;105:211-7.
13. Lednicky JA, Arrington AS, Stewart AR, et al. Natural isolates of simian virus 40 from immunocompromised monkeys display extensive genetic heterogeneity: new implications for polyomavirus disease. J Virol 1998;72:3980-90.
14. Lednicky JA, Garcea RL, Bergsagel DJ, Butel JS. Natural SV40 strains are present in human choroid plexus and ependymoma tumors. Virology 1995;212:710-7.
15. Yajima T, Yagihashi A, Kameshima H, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 1998;44:2441-5.
16. Wallis C, Melnick JL. Stabilization of poliovirus by cations. Tex Rep Biol Med 1961;19:683-700.
17. Girardi AJ, Sweet BH, Hilleman, MR. Factors influencing tumor induction in hamsters by vacuolating virus, SV. Proc Soc Exp Biol Med 1963;112:662-7.
18. Krieg P, Scherer G. Cloning of SV40 genomes from human brain tumors. Virology 1984;138:336-40.
19. Brock B, Kellehr L, Zlotnick B. Product quality control testing for the oral polio vaccine. Dev Biol Stand 1998;94:217-9.
20. Kops SP. Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents. Anticancer Res 2000;20:4745-50.
21. Hayflick L, Plotkin SA, Norton TW, Koprowski H. Preparation of poliovirus vaccines on human fetal diploid cell strains. Am J Hyg 1962;75:240-58.
22. Dang-Tan T, Mahumud SM, Puntoni R, Franco EL. Polio vaccines, simian virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 2004;23:6535-40.
23. Hirvonen A, Mattson K, Karjalainen A, et al. Simian virus 40 (SV40)-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines. Mol Carcinog 1999;26:93-9.
24. Emri S, Kocagoz T, Olut A, Gungen Y, Mutti L, Baris YI. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res 2000;20:891-4.
25. De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 2002;84:455-9.
26. Leithner A, Weinhaeusel A, Windhager R, et al. Absence of SV40 in Austrian tumors correlates with low incidence of mesotheliomas. Cancer Biol Ther 2002;1:375-9.
27. Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V. Clinical and serologic responses in volunteers given vacuolating virus (SV40) by respiratory route. Proc Soc Exp Biol Med 1961;109:56-9.
28. Melnick JL, Stinbaugh S. Excretion of vacuolating SV40 after ingestion as a contaminant of oral polio vaccine. Proc Soc Exp Biol Med 1962;109:965-8.
29. Nurgalieva ZZ, Wong C, Zhangabylov AK, et al. Polyomavirus SV40 infections in Kazakhstan. J Infect 2005;50:142-8.
30. Koprowski H, Ponten JA, Jensen F, Ravdin RG, Moorhead P, Saksela E. Transformation of cultures of human tissue infected with simian virus SV40. J Cell Comp Physiol 1962;59:281-92.
31. Jensen F, Koprowski H, Pagano JS, Ponten J, Ravdin RG. Autologous and homologous implantation of human cells transformed in-vitro by SV40. J Natl Cancer Inst 1964;32:917-37.
32. Bocchetta M, Di Resta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000;97:10214-9.
33. Yu J, Boyapati A, Rundell K. Critical role for SV40 small t-antigen in human cell transformation. Virology 2001;290:192-8.
34. Jasani B, Cristaudo A, Emri SA, et al. Association of SV40 with human tumors. Semin Cancer Biol 2001;11:49-61.
35. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004;364:1157-66.
36. Aldieri E, Orecchia S, Ghigo D, et al. Simian virus 40 infection down-regulates the expression of nitric oxide synthetase in human mesothelial cells. Cancer Res 2004;64:4082-4.
37. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiological study. Cancer Res 2005;65:3049-52.
38. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65:5256-62.